Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093959 · ClinicalTrials.gov registry record · Phase 2
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 2
- Study locations
NCT05093959: Active Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by Wake Forest University Health Sciences.
NCT05093959 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 86 participants, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05093959, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 2
- Study locations
Study Summary
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with preserved ejection fraction (HFpEF).
Primary Outcome
Peak VO2 (ml of O2 relative to kg of body weight per minute \[ml/kg/min\]) is a measure of peak oxygen capacity during exercise, is a standardized, objective, reproducible and valid measure of exercise capacity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
Study Locations (2)
North Carolina
- Atrium Health Sanger Heart and Vascular Clinic Institute - Charlotte
- Wake Forest School of Medicine - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT05093959 still lists
NCT05093959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05093959 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05093959 about?
NCT05093959 is a clinical study titled "Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction". Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with prese...
What is the current status of trial NCT05093959?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2022-01-04. Estimated completion is 2026-04.
What conditions does trial NCT05093959 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT05093959?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT05093959?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05093959 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05093959's enrollment target sits among peer trials
86 20th of 42 higher than 23 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
RECRUITING · Phase 2
-
Study of JK07 in Patients With Chronic Heart Failure
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
RECRUITING · Phase 2
-
Cilostazol for HFpEF
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI